BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 25832652)

  • 21. Emerging treatments for classical myeloproliferative neoplasms.
    Vannucchi AM; Harrison CN
    Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 23. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
    Bose P; Verstovsek S
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The anti-proliferative and anti-inflammatory mechanisms of JAK1 inhibitor SHR0302 versus Ruxolitinib in SET2 cell line and primary cells].
    Yang AY; Liu JQ; Cai YN; Fang MY; Yang L; Chen M; Li B; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1003-1007. PubMed ID: 32023730
    [No Abstract]   [Full Text] [Related]  

  • 28. Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.
    Guglielmelli P; Rotunno G; Bogani C; Mannarelli C; Giunti L; Provenzano A; Giglio S; Squires M; Stalbovskaya V; Gopalakrishna P; Vannucchi AM;
    Br J Haematol; 2016 Jun; 173(6):938-40. PubMed ID: 26303809
    [No Abstract]   [Full Text] [Related]  

  • 29. The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.
    Cardoso BA; Belo H; Barata JT; Almeida AM
    PLoS One; 2015; 10(12):e0143897. PubMed ID: 26623653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
    Verstovsek S; Yeleswaram S; Hou K; Chen X; Erickson-Viitanen S
    Hematol Oncol; 2018 Oct; 36(4):701-708. PubMed ID: 30105794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
    Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
    Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
    Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
    Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety evaluation of ruxolitinib for treating myelofibrosis.
    Galli S; McLornan D; Harrison C
    Expert Opin Drug Saf; 2014 Jul; 13(7):967-76. PubMed ID: 24896661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
    Heine A; Held SA; Daecke SN; Wallner S; Yajnanarayana SP; Kurts C; Wolf D; Brossart P
    Blood; 2013 Aug; 122(7):1192-202. PubMed ID: 23770777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.
    Curran SA; Shyer JA; St Angelo ET; Talbot LR; Sharma S; Chung DJ; Heller G; Hsu KC; Betts BC; Young JW
    Cancer Immunol Res; 2017 Jan; 5(1):52-60. PubMed ID: 27923824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-associated skin lesions in a patient with myelofibrosis receiving ruxolitinib.
    Fournier JB; Cummings F; Cannella J; Breen C; Zhou L; Iwamoto S
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
    Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
    J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.